Gan & Lee Pharmaceuticals. (SHA:603087)
China
· Delayed Price · Currency is CNY 59.81
-0.42 (-0.70%)
Apr 29, 2026, 3:00 PM CST
SHA:603087 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 1,024 | 1,144 | 614.66 | 340.07 | -439.52 | 1,453 | Upgrade
|
| Depreciation & Amortization | 303.42 | 303.42 | 252.42 | 225.26 | 200.34 | 184.88 | Upgrade
|
| Other Amortization | 1.77 | 1.77 | 6.8 | 1.77 | 1.77 | 1.74 | Upgrade
|
| Loss (Gain) From Sale of Assets | -3.71 | -3.71 | -158.48 | 17.58 | 80.17 | 0 | Upgrade
|
| Asset Writedown & Restructuring Costs | -36.63 | -36.63 | 5.73 | 13.38 | 46.58 | 1.69 | Upgrade
|
| Loss (Gain) From Sale of Investments | -290.78 | -290.78 | -61.25 | -63.33 | -87.57 | -85.63 | Upgrade
|
| Provision & Write-off of Bad Debts | - | - | -20.15 | 15.96 | 27.25 | 19.39 | Upgrade
|
| Other Operating Activities | 65.83 | -66.53 | -78.34 | -43.57 | -50.7 | -141.11 | Upgrade
|
| Change in Accounts Receivable | -364.48 | -364.48 | 132.15 | 480.76 | 2,224 | -155.18 | Upgrade
|
| Change in Inventory | -28.87 | -28.87 | -203.04 | -239.14 | -35.44 | -158.47 | Upgrade
|
| Change in Accounts Payable | 106.22 | 106.22 | -37.49 | -665.1 | -1,546 | -30.39 | Upgrade
|
| Change in Other Net Operating Assets | 73.59 | 73.59 | 112.85 | 50.11 | 19.59 | - | Upgrade
|
| Operating Cash Flow | 797.2 | 784.28 | 537.31 | 109.45 | 296.68 | 1,078 | Upgrade
|
| Operating Cash Flow Growth | 29.68% | 45.96% | 390.91% | -63.11% | -72.48% | -13.14% | Upgrade
|
| Capital Expenditures | -1,077 | -926.09 | -440.8 | -553.06 | -983.44 | -692.08 | Upgrade
|
| Sale of Property, Plant & Equipment | -0.07 | 0.75 | - | 0.36 | 0.06 | 1.02 | Upgrade
|
| Divestitures | 309.62 | 309.62 | - | - | - | - | Upgrade
|
| Investment in Securities | 429.51 | 559.09 | 87.94 | -744.48 | 328.42 | 56.66 | Upgrade
|
| Other Investing Activities | 92.36 | 92.61 | 90.83 | 319.78 | 212.52 | 136.27 | Upgrade
|
| Investing Cash Flow | -245.92 | 35.98 | -262.03 | -977.4 | -442.45 | -498.13 | Upgrade
|
| Long-Term Debt Repaid | - | - | -1.99 | -5.03 | - | - | Upgrade
|
| Net Debt Issued (Repaid) | - | - | -1.99 | -5.03 | - | - | Upgrade
|
| Issuance of Common Stock | 2 | - | 139.32 | 759.73 | 71.36 | - | Upgrade
|
| Repurchase of Common Stock | - | - | -17.49 | - | - | - | Upgrade
|
| Common Dividends Paid | -597.53 | -597.53 | -420.55 | - | -168.46 | -224.62 | Upgrade
|
| Other Financing Activities | -65.28 | -140.25 | - | - | -3.77 | -4.32 | Upgrade
|
| Financing Cash Flow | -660.8 | -737.77 | -300.71 | 754.7 | -100.87 | -228.93 | Upgrade
|
| Foreign Exchange Rate Adjustments | -2.37 | 1.17 | -0.95 | 2.36 | 4.19 | -2.68 | Upgrade
|
| Net Cash Flow | -111.88 | 83.65 | -26.38 | -110.89 | -242.44 | 348.43 | Upgrade
|
| Free Cash Flow | -280.13 | -141.81 | 96.51 | -443.61 | -686.76 | 386.09 | Upgrade
|
| Free Cash Flow Growth | - | - | - | - | - | -41.43% | Upgrade
|
| Free Cash Flow Margin | -7.10% | -3.50% | 3.17% | -17.01% | -40.11% | 10.69% | Upgrade
|
| Free Cash Flow Per Share | -0.47 | -0.24 | 0.16 | -0.78 | -1.22 | 0.69 | Upgrade
|
| Cash Income Tax Paid | 244.77 | 156.1 | 100.19 | -5 | 116.25 | 323.56 | Upgrade
|
| Levered Free Cash Flow | -864.83 | -724.95 | 78.76 | -635.98 | -149.69 | 171.67 | Upgrade
|
| Unlevered Free Cash Flow | -864.83 | -724.95 | 78.94 | -635.64 | -149.21 | 172.28 | Upgrade
|
| Change in Working Capital | -266.84 | -266.84 | -24.09 | -397.66 | 518.36 | -355.55 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.